scorecardresearch
Wednesday, Nov 30, 2022

Optimus concludes phase 3 clinical trial of oral Covid drug with promising results

According to the final clinical trial report, the study found that on the fifth day, 78.4% of the patients in the treatment group were recorded RT-PCR negative compared to 48.2% in the placebo group.

pune covid news, new covid drug, new covid oral drug, OPTIMUS GROUP, Molnupiravir, new covid treatment, Molnupiravir drug trials, oral treatment for covid, pune news todayIn a statement issued on Thursday, the pharmaceutical company said that it was the first to file for Phase 3 clinical trial of molnupiravir with the Central Licensing Authority. There were 29 study sites across the country. (Representative Image)

OPTIMUS GROUP has announced the successful completion of the Molnupiravir oral capsule phase 3 clinical trial. Molnupiravir is a new oral treatment for individuals with Covid-19 infection. The experimental antiviral drug is being evaluated by US FDA for its effectiveness and safety.

The advisory committee will meet on November 30 to take up Merck and Ridgeback’s request for granting EUA for molnupiravir to treat mild to moderate Covid infection.

On May 18, 2021, it received approval from the Drugs Controller General of India (DCGI) to conduct the trial according to the recommendations of the subject expert committee (SEC) of the CDSCO, DGHS, Ministry of Health and Family Welfare.

Subscriber Only Stories
Let’s just stop calling soil “dirt”Premium
Money to fight climate change: Are taxes the answer?Premium
Gujarat elections | Sitting MLA in the shade; it’s a Yogi Adityanath show...Premium
Delhi Confidential: In Ladakh, a push for employment to youth of minority...Premium

In a statement issued on Thursday, the pharmaceutical company said that it was the first to file for Phase 3 clinical trial of molnupiravir with the Central Licensing Authority. There were 29 study sites across the country.

“Optimus is prepared to ensure manufacturing and distribution of molnupiravir efficiently and effectively,” Dr D Srinivas Reddy, Chairman and Managing Director Optimus Pharma said.

According to the final clinical trial report, the study found that on the fifth day, 78.4% of the patients in the treatment group were recorded RT-PCR negative compared to 48.2% in the placebo group. On the 10th day, 91.5% of the patients in the treatment group were recorded RT-PCR negative compared to 43% in the placebo group.

First published on: 29-10-2021 at 05:43:38 am
Next Story

Pune: Rs 25 lakh siphoned off from BJMC account using fake cheque

Latest Comment
Post Comment
Read Comments
Advertisement
Advertisement
Advertisement
Advertisement
close